Prescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?

Prescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?

Bibliographic Details
Main Authors:	Fiammetta Cosci, Giovanni A. Fava
Format:	Article
Language:	English
Published:	Karger Publishers 2021-11-01
Series:	Biomedicine Hub
Online Access:	https://www.karger.com/Article/FullText/519656

Similar Items

MRI predictors of pharmacotherapy response in major depressive disorder
by: Andrew R. Gerlach, et al.
Published: (2022-01-01)

The moderating role of stigma in the relationship between depression and resilience: results of a cross-sectional study in university students
by: Caroline Rometsch, et al.
Published: (2024-04-01)

Efficacy of Pharmacotherapy and Cognitive Therapy, Alone and in Combination in Major Depressive Disorder
by: Alireza Rahimi, et al.
Published: (2008-06-01)

Anxiety in the Medically Ill: A Systematic Review of the Literature
by: Sara Romanazzo, et al.
Published: (2022-06-01)

Psychotherapy, pharmacotherapy, and their combination in the treatment of major depressive disorder: How well are we making use of available therapies?
by: Nădășan Ingrid Karina, et al.
Published: (2023-12-01)

Psychodramatic psychotherapy combined with pharmacotherapy in major depressive disorder: an open and naturalistic study
by: Elisabeth Maria Sene Costa, et al.
Published: (2006-03-01)

The psychological development of panic disorder: implications for neurobiology and treatment O desenvolvimento psicológico do transtorno de pânico: implicações para a neurobiologia e o tratamento
by: Fiammetta Cosci
Published: (2012-06-01)

Major depressive disorder: mechanism-based prescribing for personalized medicine
by: Saltiel PF, et al.
Published: (2015-03-01)

To die or not to die: how does p53 decide?
by: Slee, E, et al.
Published: (2004)

Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine
by: Dan J. Stein
Published: (2023-04-01)

The Emerging Role of Clinical Pharmacopsychology
by: Fiammetta Cosci, et al.
Published: (2019-06-01)

S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review
by: Alessandro Cuomo, et al.
Published: (2020-09-01)

Prescribing Clinicians’ Perspectives on Evidence-Based Psychotherapy for Posttraumatic Stress Disorder
by: Erin R. Barnett, et al.
Published: (2014-10-01)

Depressive disorders at general practitioner’s office – diagnostics and pharmacotherapy
by: Piotr Krawczyk
Published: (2014-06-01)

Deciding how to decide: Using the Digital Preservation Storage Criteria
by: Schaefer, Sibyl K, et al.
Published: (2021)

Catatonia in a case of major depression resistant to pharmacotherapy. A case report
by: C. M. Gil Sánchez, et al.
Published: (2023-03-01)

Clinimetric properties of the 21-item Depression, Anxiety and Stress Scales (DASS-21)
by: Giovanni Mansueto, et al.
Published: (2023-08-01)

Pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report
by: M. I. Husain, et al.
Published: (2023-03-01)

Pharmacotherapy in Autism Spectrum Disorder: How, When and Why
by: Grazia Maria Giovanna Pastorino, et al.
Published: (2020-04-01)

Pharmacotherapy in mania and depression
by: Grunze Heinz
Published: (2008-04-01)

The pharmacotherapy of depression with EPA
by: Puri Basant K
Published: (2010-04-01)

Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study
by: Antonio Del Casale, et al.
Published: (2022-02-01)

How to decide business policy
by: 3999 Intermediate Technology Development Group
Published: (1969)

Macro-engineering : how to decide?
by: Jones, William J.
Published: (2006)

Psychosocial interventions to improve adherence in depressed and anxious older adults prescribed antidepressant pharmacotherapy: a scoping review
by: Sarah T. Stahl, et al.
Published: (2023-11-01)

Prediction of health care expenditure increase: how does pharmacotherapy contribute?
by: Annika M. Jödicke, et al.
Published: (2019-12-01)

Ongoing pharmacotherapy maintains quality of life benefits in older adults with major depression.
by: Natarajan, M, et al.
Published: (2008)

Antipsychotics in child and adolescent patients with major depressive disorder: A retrospective analysis of prescribing patterns
by: Danielle Dauchot, PharmD, et al.
Published: (2024-02-01)

Association of pharmacotherapy with clinicians' nutritional counseling practices to diabetic and hypertensive patients
by: Deldar Morad Abdulah, et al.
Published: (2021-01-01)

Rational pharmacotherapy of major vaginal diseases
by: A G Kedrova
Published: (2014-02-01)

How could stress lead to major depressive disorder?
by: Gal Richter-Levin, et al.
Published: (2018-06-01)

EVALUATION OF THE EFFICACY OF DEPRESSIVE DISORDERS PHARMACOTHERAPY USING QUANTITATIVE PHARMACO-EEG
by: O. M. Kudelina, et al.
Published: (2018-12-01)

251 A Mixed Methods Study of Patient and Clinician Views and Experiences of Pharmacogenomic Testing for Major Depressive Disorder
by: Katherine Hendy, et al.
Published: (2023-04-01)

COMPLEX ASSESSMENT OF EFFICACY OF STATINS PRESCRIBED AT MOST BY CLINICIANS
by: A. S. Sivkov, et al.
Published: (2018-06-01)

Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances
by: Ana Salomé Correia, et al.
Published: (2024-03-01)

Pharmacotherapy of depression in palliative patients
by: Paulina Trawka, et al.
Published: (2019-08-01)

Pharmacotherapy of depression in palliative patients
by: Paulina Trawka, et al.
Published: (2019-08-01)

Clinicians’ perspectives of health related quality of life and priorities in deciding management for malignant pleural effusion
by: Sivakumar, P, et al.
Published: (2016)

How Do Autonomous Vehicles Decide?
by: Sumbal Malik, et al.
Published: (2022-12-01)

How do the Constitutional Courts decide?
by: Pasquale Pasquino
Published: (2016-12-01)